Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss.
Hope DCD, Hinds CE, Lopes T, Vincent ML, Shrewsbury JV, Yu ATC, Davies I, Scott R, Jones B, Murphy KG, Minnion JS, Sardini A, Carling D, Lutz TA, Bloom SR, Tan TMM, Owen BM. Hope DCD, et al. Among authors: carling d. Cell Rep Med. 2022 Nov 15;3(11):100810. doi: 10.1016/j.xcrm.2022.100810. Cell Rep Med. 2022. PMID: 36384093 Free PMC article.
AMPK activation protects against prostate cancer by inducing a catabolic cellular state.
Penfold L, Woods A, Pollard AE, Arizanova J, Pascual-Navarro E, Muckett PJ, Dore MH, Montoya A, Whilding C, Fets L, Mokochinski J, Constantin TA, Varela-Carver A, Leach DA, Bevan CL, Nikitin AY, Hall Z, Carling D. Penfold L, et al. Among authors: carling d. Cell Rep. 2023 Apr 25;42(4):112396. doi: 10.1016/j.celrep.2023.112396. Epub 2023 Apr 15. Cell Rep. 2023. PMID: 37061917 Free PMC article.
Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Constantin TA, Varela-Carver A, Greenland KK, de Almeida GS, Olden E, Penfold L, Ang S, Ormrod A, Leach DA, Lai CF, Ainscow EK, Bahl AK, Carling D, Fuchter MJ, Ali S, Bevan CL. Constantin TA, et al. Among authors: carling d. Br J Cancer. 2024 Mar;130(5):892. doi: 10.1038/s41416-024-02606-w. Br J Cancer. 2024. PMID: 38355841 Free PMC article. No abstract available.
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Constantin TA, Varela-Carver A, Greenland KK, de Almeida GS, Olden E, Penfold L, Ang S, Ormrod A, Leach DA, Lai CF, Ainscow EK, Bahl AK, Carling D, Fuchter MJ, Ali S, Bevan CL. Constantin TA, et al. Among authors: carling d. Br J Cancer. 2023 Jun;128(12):2326-2337. doi: 10.1038/s41416-023-02252-8. Epub 2023 Apr 19. Br J Cancer. 2023. PMID: 37076563 Free PMC article.
Hepatocyte cholesterol content modulates glucagon receptor signalling.
McGlone ER, Ansell TB, Dunsterville C, Song W, Carling D, Tomas A, Bloom SR, Sansom MSP, Tan T, Jones B. McGlone ER, et al. Among authors: carling d. Mol Metab. 2022 Sep;63:101530. doi: 10.1016/j.molmet.2022.101530. Epub 2022 Jun 16. Mol Metab. 2022. PMID: 35718339 Free PMC article.
Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma.
Nijhuis A, Sikka A, Yogev O, Herendi L, Balcells C, Ma Y, Poon E, Eckold C, Valbuena GN, Xu Y, Liu Y, da Costa BM, Gruet M, Wickremesinghe C, Benito A, Kramer H, Montoya A, Carling D, Want EJ, Jamin Y, Chesler L, Keun HC. Nijhuis A, et al. Among authors: carling d. Nat Commun. 2022 Mar 16;13(1):1380. doi: 10.1038/s41467-022-28907-3. Nat Commun. 2022. PMID: 35296644 Free PMC article.
199 results